Initiator Pharma Investor Relations Material

Initiator Pharma A/S is a clinical stage life science company developing drugs targeting unmet medical needs within the central and peripheral nervous system. The company's pipeline includes IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for treating severe neuropathic pain. In pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain and IPDP2015 for depression. Founded in 2016, Initiator Pharma A/S operates an R&D center in Copenhagen, Denmark.